Tang X, Takekoshi S, Itoh J, et al. Somatostatin analogue inhibits the mobility of prostate carcinoma cells: a new therapeutic method for advanced prostate carcinoma[J]. Int J Oncol, 2010, 37(5): 1077-1083.
[2]
Cerovac V, Monteserin-Garcia J, Rubinfeld HT, et al. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells[J]. Cancer Res, 2010, 70(2): 666-674.
Songgang L, Jiyu L, Gongwei, et al. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to Sphase rather than through the P53/Bax-depended apoptosis way in vitro[J]. Hepatogastroenterology, 2009, 56(95): 1253-1260.
[6]
[ 1 ] Srikant CB, Shen SH. Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells[J]. Endocrinology, 1996, 137(8): 3461-3468.
[7]
[ 2 ] Sharma K, Patel YC, Srikant CB. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest[J]. Mol Endocrinol, 1999, 13(1): 82-90.
[8]
[ 3 ] Bousquet C, Puente E, Buscail L, et al. Antiproliferative effect of somatostatin and analogs [J]. Chemotherapy, 2001, 47(1): 30-39.
[9]
[ 4 ] Theodoropoulou M, Zhang J, Laupheimer S, et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing zac1 expression[J]. Cancer Res, 2006, 66(3): 1576-1582.
[10]
[ 5 ] Pagès P, Benali N, Saint-Laurent N, et al. Sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1) Evidence for the role of SHP-1[J]. J Biol Chem, 1999, 274(21): 15186-15193.
[11]
[ 6 ] Held-Feindt J, Forstreuter F, Pufe T, et al. Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells[J]. Brain Res Mol Brain Res, 2001, 87(1): 12-21.
[12]
[ 7 ] Dent P, Wang Y, Gu YZ, et al. S49 cells endogenously express subtype 2 somatostatin receptors which couple to increase protein tyrosine phosphatase activity in membranes and down-regulate Raf-1 activity in situ[J]. Cell Signal, 1997, 9(7): 539-549.
[13]
[ 8 ] Reardon DB, Dent P, Wood SL, et al. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-tran sformed NIH3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness[J]. Mol Endocrinol, 1997, 11(8): 1062-1069.
[14]
[ 9 ] Florio T, Yao H, Carey KD, et al. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1)[J]. Mol Endocrinol, 1999, 13(1): 24-37.
[15]
Alderton F, Humphrey PP, Sellers LA, et al. High-intensity p38 kinase activity is critical for p21(cip1) induction and the antiproliferative function of G(i) protein-coupled receptors[J]. Mol Pharmacol, 2001, 59(5): 1119-1128.
[16]
Massa A, Barbieri F, Aiello C, et al. The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2[J]. Ann N Y Acad Sci, 2004, 1030: 264-274.
[17]
Kuriyama I, Miyazaki A, Tsuda Y. Inhibitory effect of somatostatin Peptide analogues on DNA polymerase activity and human cancer cell proliferation[J]. Anticancer Res, 2010, 30(12): 4841-4849.
[18]
Li M, Wang XC, Li W, et al. Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer[J]. Cancer Sci, 2008, 99(11): 2218-2223.
[19]
Zhou T, Xiao X, Xu B, et al. Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways[J]. Acta Oncol, 2009, 48(3): 401-410.
Guillermet GJ, Saint LN, Davenne L, et al. Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways[J]. Cell Death Differ, 2007, 14(2): 197-208.
[22]
Georgiadou M, Notas G, Xidakis C, et al. TNF receptors in Kupffer cells[J]. J Recept Signal Transduct Res, 2011, 4(31): 291-298.
[23]
Boros LG, Brandes JL, Yusut FI, et al. Inhibition of the oxidtive and nonoxidative pentose pho -sphato pathways by somatostation：apsssible mechanism of antitumor action[J]. Med Hypotheses, 1998, 50(6): 501-506.
[24]
Liu ZR, Qin RY, Wu GS. Effect of octreotide on human pancreatic cancer cells after transfected with somatostatin receptor type 2 gene[J]. World J Gastroenterol, 2004, 10(1-5): 2292-2294.
[25]
Laklai H, Laval S, Dumartin L, et al. Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer[J]. Proc Natl Acad Sci USA, 2009, 10(42): 17769-17774.
[26]
Thangaraju M , Shanua K, Liu D, et al. In terdependent regulation of intracellular acidification and SHP-1 in apoptosis[J]. Cancer Res, 1999, 59(7): 1649-1654.
[27]
Arena S, Pattarozzi A, Corsaro A, et al. Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways[J]. Mol Endocrinol, 2005, 19(1): 255-267.
Buscail L, Vernejoul F, Faure P, et al. Regulation of cell proliferation by somatostatin[J]. Ann Endocrinol, 2002, 63(2): 13-18.
[31]
Yamaguchi M, Yamada Y, Hosokawa Y, et al. Long-term suppressive effect of octreotide on pro gression of metastatic gastrinoma with multiple endocrine neoplasia type 1: seven-year follow up[J]. Intern Med, 2010, 49(15): 1557-1563.
[32]
Ishii A, Imanishi Y, Kobayashi K, et al. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels[J]. Calcif Tissue Int, 2010, 86(6): 455-462.
[33]
Friedlander TW, Weinberg VK, Small EJ, et al. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: Results of a phase II study[J]. Urol Oncol, 2010, 1873-2496.
[34]
He Y, Yuan XM, Lei P, et al. The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells[J]. Acta Pharmacol Sin, 2009, 30(7): 1053-1059.
[35]
Ludvigsen E, Stridsberg M, Taylor JE, et al. Subtype selective interactions of somatostatin and somatostatin analogs with SST1, SST2, and SST5 in BON-1 cells[J]. Med Oncol, 2004, 21(3): 285-295.
[36]
Feng Y, Huang T, Gao J, et al. Inhibition of metastatic progression of SSTR2 gene transfection mediated by adenovirus in human pancreatic carcinoma cells[J]. J Huazhong Univ Sci Technolog Med Sci, 2006, 26(1): 68-71.
[37]
Kumar M, Liu ZR, Thapa L, et al. Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metallo -proteinase-2 expression in vitro[J]. World J Gastroenterol, 2004, 10(3): 393-399.
[38]
Benali N, Cordelier P, Calise D, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238[J]. Proc Natl Acad Sci USA, 2000, 97(16): 9180-9185.
